Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the
American Thoracic Society (ATS), European Respiratory Society (ERS), and The World
Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is 20-40 mg per day.5
The exact dose and duration of treatment for sarcoidosis are unknown.4 We hypothesize that a
higher dose of 40 mg per day as compared to a 20 mg/day dose of prednisone will be more
effective in preventing post-treatment relapse by effective initial suppression of the
granulomatous inflammation and reduction of the disease load. In this study, we compare the
efficacy and safety of medium dose (40 mg/day prednisone) and low dose (20 mg/day prednisone)
glucocorticoids in the treatment of acute sarcoidosis.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research